SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
12.49 ^CNY	+0.56%		+6.75%	+27.58%

12/07	Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	MT
09/07	Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	MT

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

January 06, 2023

On January 6, 2022, Shanghai Shyndec Pharmaceutical Co., Ltd. closed the transaction. The company has received CNY 1,199,999,998.87, and the actual net amount of funds raised after deducting various issuance expenses was CNY 1,186,915,363.01.

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	12/07	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	09/07	MT
Shyndec Pharma Unit Gets China Nod for Analgesic Ingredient	14/06	MT
Shyndec Pharma Unit Gets China Nod for Conjunctivitis Eye Drops	14/06	MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	15/05	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	16/04	MT
China stocks rise after new guidelines; HK shares drop	15/04	RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	10/04	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	27/03	MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	07/03	MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	21/02	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	20/02	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/01	CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	03/01	MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	08/12	MT
Shyndec Pharma Passes Drug GMP Compliance Inspection	28/11	MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	08/11	MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	07/11	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	19/23/19	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	18/23/18	CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	14/23/14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	06/23/06	MT

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

More charts

Company Profile

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

12.49

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+27.58%	230.61Cr
KYOWA KIRIN CO. LTD.	+34.09%	1.03TCr
YUHAN CORPORATION	+40.84%	522.86Cr
SK BIOPHARMACEUTICALS CO., LTD.	-18.53%	462.47Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+12.65%	352.27Cr
BETTA PHARMACEUTICALS CO., LTD.	-39.96%	178.31Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.87%	168.96Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr
SUPERNUS PHARMACEUTICALS, INC.	0.00%	159.1Cr
INDIVIOR PLC	-33.26%	135.83Cr

Specialty & Advanced Pharmaceuticals